---
schema_version: "secwatch.filing_event.v1"
accession: "0000200406-24-000048"
form_type: "8-K"
ticker: "JNJ"
cik: "0000200406"
company_name: "JOHNSON & JOHNSON"
filed_at: "2024-05-01T23:59:59+00:00"
generated_at: "2026-06-03T03:18:58.163389+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# JNJ proposes $6.475B talc settlement plan; Q1 GAAP EPS cut to $1.34

## Summary
- Proposed plan pays $6.475B present value ($8.4B nominal over 25 years) to resolve all ovarian cancer cosmetic talc claims.
- Incremental $2.7B charge; total talc reserve now ~$11B present value ($13.7B nominal) as of Q1 2024.
- Previously reported GAAP net earnings reduced from $5.4B to $3.3B; EPS from $2.20 to $1.34 for Q1 2024.
- Q1 2024 adjusted EPS of $2.71 unchanged; sales $21.38B (+2.3% YoY).
- No impact to mesothelioma, state consumer claims; plan excludes those categories.

## SEC filing metadata
- accession: 0000200406-24-000048
- form_type: 8-K
- ticker: JNJ
- cik: 0000200406
- company_name: JOHNSON & JOHNSON
- filed_at: 2024-05-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/200406/000020040624000048/0000200406-24-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/200406/000020040624000048/jnj-20240501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000200406-24-000048
- JSON: https://secwatch.observer/filing/0000200406-24-000048.json
- Plain text: https://secwatch.observer/filing/0000200406-24-000048.txt

## Key facts
- Earnings Releases
  JOHNSON & JOHNSON reported first quarter ended March 31, 2024 results: revenue $21,383, net income $3,255, EPS $1.34.
  - Period: first quarter ended March 31, 2024
  - Revenue: $21,383
  - Net income: $3,255
  - EPS: $1.34
  - Result: reported results
  source text: (Unaudited; in Millions Except Per Share Figures) FIRST QUARTER 2024 2023 Percent Percent Percent Increase Amount to Sales Amount to Sales (Decrease) Sales to customers $ 21,383 100.0 $ 20,894 100.0 2.3 Cost of products sold 6,511 30.4 6,687 32.0 (2.6) Gross Profit 14,872 69.6 14,207 68.0 4.7 Selling, marketing and administrative expenses 5,257 24.6 4,906
  evidence_url: https://www.sec.gov/Archives/edgar/data/200406/000020040624000048/0000200406-24-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.